Carbinoxamine

Carbinoxamine

File:Carbinoxamine.svg
Systematic (IUPAC) name
2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N,N- dimethyl-ethanamine
Clinical data
Pregnancy category	C
Routes of administration	Oral: 4 mg tablet or 4 mg/5 mL liquid
Legal status
Legal status	4 mg is FDA approved
Pharmacokinetic data
Biological half-life	10 to 20 hours
Identifiers
CAS Number	486-16-8
ATC code	R06AA08 (WHO)
PubChem	CID 2564
DrugBank	APRD00765
ChemSpider	2466
Chemical data
Formula	C16H19ClN2O
Molar mass	290.788 g/mol[[]]
(verify)

Carbinoxamine (Clistin, Palgic) antihistamine and anticholinergic. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. It is now available under the brand name Palgic as 4 mg tablets or 4 mg/5 mL liquid. It is approved by the U.S. Food and Drug Administration (FDA) (specifically at the 4 mg dose/strength) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis.

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed, and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older. [1]

External links

• Carbinoxamine

pt:Carbinoxamina